|
Volumn 18, Issue 12, 1997, Pages 562-563
|
Immunotherapeutic potential of bispecific antibodies
|
Author keywords
[No Author keywords available]
|
Indexed keywords
B LYMPHOCYTE ANTIGEN;
BISPECIFIC ANTIBODY;
CANCER ANTIBODY;
CD16 ANTIGEN;
COMPLEMENT RECEPTOR;
FC RECEPTOR;
GAMMA INTERFERON;
GRANULOCYTE COLONY STIMULATING FACTOR;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
MDX 447;
MDX H 210;
T LYMPHOCYTE RECEPTOR;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
AUTOIMMUNE DISEASE;
B CELL LYMPHOMA;
CANCER IMMUNOTHERAPY;
CLINICAL TRIAL;
COLORECTAL CANCER;
EFFECTOR CELL;
HODGKIN DISEASE;
HUMAN;
IDIOPATHIC THROMBOCYTOPENIC PURPURA;
MOUSE;
NATURAL KILLER CELL;
NONHUMAN;
ONCOGENE NEU;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
SHORT SURVEY;
SOLID TUMOR;
T LYMPHOCYTE;
|
EID: 0031466808
PISSN: 01675699
EISSN: None
Source Type: Journal
DOI: 10.1016/S0167-5699(97)01167-5 Document Type: Note |
Times cited : (39)
|
References (14)
|